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Comparative Effectiveness of Abatacept versus Anti-TNF 
agents in the Treatment of Biologic Naïve Rheumatoid 
Arthritis Patient Using the CORRONA Registry
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CORRONA
Consortium of Rheumatology 
Researchers of North America  
(CORRONA)
• Gathers information on arthritis, 
comorbidities, functional status, 
medications, adverse events 
and outcomes from both 
patients and providers
• Includes over 100 practice sites 
• 37 states across the US
• 80% private practice and 20% 
academic
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OBJECTIVES
• The objective of this study was to compare the 
effectiveness of abatacept to anti-TNFs using 
the following:
– Change in disease activity based on the Clinical 
Disease Activity Index (CDAI) 
– Achievement of remission based on the CDAI 
METHODS
• Study setting:  The Consortium of Rheumatology Researchers of North 
America (CORRONA) registry is a prospective observational cohort of 
>20,000 RA patients
• Study Population:
– Visits between 2/20/02 and 12/14/09
– Biologic naïve
– Not in remission at baseline
– Follow-up visit 1 year after initiation.  
– Patients who initiated abatacept or an anti-TNF were identified
– Anti-TNF initiators were matched to abatacept initiators (3 to 4:1 match) based 
on age, disease duration, use of methotrexate at time of initiation, initiation time 
frame (at or prior to index visit) and baseline CDAI
• Outcomes:  Comparative effectiveness was examined by comparing 
abatacept initiators to anti-TNF initiators 1 year after initiation on the 
following:
– Treatment response based on change in CDAI
– Achievement of remission based on the CDAI
• Analyses:
– Three analytic approaches were used
– Intention to treat (ITT): all initiators were included in these analyses
– Nonresponder imputation: nonresponse was imputed for those who 
discontinued for reasons other than toxicity and last response if due to 
toxicity
– Completers analysis: included only those who remained on drug
– Regression models were performed to adjust for clustering by physician 
and by matched clusters as well baseline differences.
METHODS
Table 1.  Baseline characteristics of abatacept and 
matched anti-TNF initiators
Characteristic Abatacept initiators
N=36
Anti-TNF initiators
N=139
P value
Female (%) 81 78 0.81
Age (in years) 66 65 0.41
Private insurance (%) 71 71 1.00
Medicaid (%) 6 7 1.00
Medicare (%) 65 55 0.41
No insurance (%) 3 1 0.42
Disabled (%) 3 13 0.19
Duration of RA (mean years, ±SD) 11.5 (10.1) 10.6 (8.6) 0.65
CDAI (mean, ±SD) 16.5 (11.0) 18.0 (10.0) 0.44
Tender joint count (mean, ±SD) 4.7 (5.9) 5.1 (5.0) 0.72
Swollen joint count (mean, ±SD) 5.8 (4.4) 6.0 (4.6) 0.86
Physician global (mean, ±SD) 24.9 (18.3) 32.3 (19.0) 0.04
Patient global (mean, ±SD) 34.7 (20.2) 37.0 (24.9) 0.60
Morning stiffness RA (mean hours, ±SD) 1.1 (1.6) 1.3 (1.8) 0.46
ESR (mean mmHg, ±SD) 22.6 (11.6) 28.4 (25.9) 0.49
Prior number of DMARDs (mean, ±SD) 1.2 (0.9) 1.2 (1.2) 0.73
Current methotrexate use (%) 71 72 1.00
Table 2. Comparison of response based on change in CDAI in 
abatacept (ABA) initiators as compared to anti TNF initiators
Intention to Treat* Completers analysis*
Mean change in CDAI in 
abatacept vs. anti-TNF 
initiators
-6.51 vs. -7.89 -8.25 vs.-9.28
Adjusted difference 0.81 (-2.54 to 4.15) -0.70  (-4.41 to 3.01)
*Not statistically significant: models adjusted for clustering by physician, matched clusters and 
baseline CDAI
Table 3. Comparison of CDAI remission in abatacept 
(ABA) initiators as compared to anti-TNF initiators
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Intention to Treat Nonresponder
imputation
Completers 
analysis
Remission (%) 36 vs 25 36 vs 19 45 vs 27
Adjusted likelihood of 
remission
1.62 (0.63-4.17) 2.21 (0.80-6.12) 1.87 (0.68-5.18)
CONCLUSIONS
• Among this small sample of RA patients in a 
real-world setting, treatment with abatacept was 
not associated with any differences in response 
or remission rates from those seen with anti-
TNFs based on mean change in CDAI and 
achievement of CDAI remission.
• This study suggests similar effectiveness of 
abatacept and anti-TNFs in biologic naïve RA 
patients.
• Further research with a larger sample size is 
needed to confirm these findings.
Clinical Trials: Investigator Initiated 
Teriparatide for Joint Erosions in RA 
• Randomized, controlled, 12-month open-label study of teriparatide in 
patients with RA and T-scores between -1.0 and -2.5 who have joint 
erosions 
– Subjects will be randomized to receive:
• Teriparatide + TNF antagonist
• TNF antagonist alone.
• Hypothesis: Combination of teriparatide + TNF antagonist will be much 
more effective at retarding erosion progression in RA then a TNF 
antagonist alone and may allow for healing of erosions
– Joint erosion scores will be significantly improved at study completion in 
patients taking teriparatide
– Teriparatide will significantly increase
– RA disease activity measures will remain stable during the study year
• Conducted at UMass Memorial Medical Center & Brigham and Women’s 
Hospital
• Funded by a grant from Lilly
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Clinical Trials: Sponsored Multi-center
Rheumatoid Arthritis
• Tocilizumab (anti-IL-6R mAB) - Hoffmann-La Roche Inc. 
– Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and 
Prevention of Structural Joint Damage During Treatment with Tocilizumab , as a 
Monotherapy and in Combination with MTX, Vs. MTX in Patients with Early Moderate to 
Severe RA (Hoffmann-La Roche Inc. - WA19926)
Ankylosing Spondylitis
• SAR153191 (anti-IL-6R mAB) - Sanofi-Aventis
– Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Evaluate Efficacy 
and Safety of SAR153191 in Patients with AS (ALIGN)
– Uncontrolled Extension Study Evaluating the Long Term Safety and Efficacy of SAR153191 
in Patients with AS (SUSTAIN)
Osteoarthritis
• Hymovis™ (Hyluronic acid) - Fidia Farmaceutici S.p.A.
– Parallel, Double-blind, Blinded Evaluator, Randomized, Placebo-controlled, Study to 
Evaluate the Safety and Effectiveness of a New Viscoelastic Hydrogel (Hymovis™) in the 
Treatment of Knee OA with an Open-label Extension
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